Housing AstraZeneca's old R&D efforts in antibiotics, Entasis files for $86M IPO
When AstraZeneca spun out its struggling antibiotics unit a few years back, the tech — and a much smaller team — was deposited into a company called Entasis. Now, that upstart has filed for an $86 million IPO to push a few of its product candidates through human trials.
The tiny Waltham company is only a fraction of what the pharma giant’s antibiotics effort used to be. At one point, the unit had 175 staffers. But it was pared down over the years until Entasis launched in 2015 with only 21 employees. Today, according to its prospectus, it employs 34.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.